The Polymorphisms at PRSS1-PRSS2 and MORC4 Loci and the Risk of Post-ERCP Pancreatitis

Table 1

Patients characteristics and result of PRSS1-PRSS2 (rs10273639) and MORC4 (rs12688220) genotypes.

	Patients with PEP ()	Patient without PEP ()	value
Age, mean (SD) (years)	60.3 (14.12)	60.2 (15.40)	0.954
Gender (female, %)	73%	61%	0.141
Risk group (high risk, %)	67%	64%	0.713
Risk factors
(i) Sphincter of Oddi dysfunction	1 (2%)	0	0.336
(ii) Precut sphincterotomy	9 (18.4%)	16 (16.5%)	0.777
(iii) Difficult cannulation	13 (25.5%)	19 (19.6%)	0.338
(iv) Pancreatic duct injection or cannulation > 3	11 (22.4%)	12 (12.4%)	0.114
PRSS1-PRSS2 genotype frequency (%)			0.642
TT	26 (65)	67 (72)
TC	13 (32.5)	25 (26.9)
CC	1 (2.5)	1 (1.1)
MORC4 genotype frequency (%)
TT (female)/T (male)	8 (22.2)/5 (38.5)	12 (20)/21 (55.3)	0.071 (female)/0.468 (male)
TC (female)	23 (63.9)	26 (44)
CC (female)/C (male)	5 (13.9)/8 (61.5)	21 (36)/17 (44.7)
PRSS1-PRSS2 allelic frequency (%)			0.493
T	65 (81.25)	159 (85.5)	RR (95% CI) = 0.81 (0.52–1.28)
C	15 (18.75)	27 (14.5)
MORC4 allelic frequency (%)			0.431
T	44 (51.8)	71 (45.8)	RR (95% CI) = 1.17 (0.83–1.66)
C	41 (48.2)	84 (54.2)

Results from 133 sample (40 cases and 93 control). PEP: post-ERCP pancreatitis.